Dasatinib-induced diffuse alveolar hemorrhage
The BCR-ABL tyrosine kinase inhibitor dasatinib is a potent treatment for chronic myeloid
leukemia (CML). However, it is associated with pulmonary toxicities. Commonly reported
dasatinib related pulmonary toxicities include pleural effusion, lung parenchymal abnormalities,
and pulmonary hypertension. Diffuse alveolar hemorrhage (DAH) during treatment with dasatinib
is very rare. To the best of our knowledge there are only two cases reported. Here we report
a 57-year-old Caucasian woman who developed acute hypoxic respiratory failure while on
dasatinib for treatment of CML. She was diagnosed with DAH suspected to be secondary to
dasatinib, after other common etiologies were ruled out. There was full recovery after stopping
dasatinib and treatment with corticosteroids.
Keywords: Dasatinib, pulmonary toxicity, diffuse alveolar hemorrhage, chronic myeloid leukemia
Copyright (c) 2021 Dhara Dave, John Kimbugwe, Randa Hazam, Saria Tasnim, Manish Patel
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All articles are published under the Creative Commons Attribution-Non-Commercial License https://creativecommons.org/licenses/by-sa/2.0/